Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

OPN-375 Effekt og sikkerhed hos unge med bilaterale næsepolypper

15. september 2026 opdateret af: Optinose US Inc.

16-ugers randomiseret dobbeltblind placebokontrolleret parallelgruppe multicenterundersøgelse, der evaluerer effektiviteten og sikkerheden af ​​OPN-375 186 μg to gange dagligt hos unge med bilaterale næsepolypper efterfulgt af 12 ugers åben behandlingsfase

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

40

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, C1411ABE
        • Fundacion CIDEA
      • Buenos Aires, Argentina, C1425BEN
        • InAER - Investigaciones en Alergia y Enfermedades Respiratorias
      • Buenos Aires, Argentina, C1180AAX
        • Sanatorio Guemes
      • Corrientes, Argentina, W3400AVV
        • Instituto de Asma Alergia y Enfermedades Respiratoria (IAAER)
      • Mendoza, Argentina, M5500CCG
        • Centro Medico INSARES
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Argentina, X5008AEV
        • Instituto Medico Rio Cuarto
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion de Estudios Clinicos - Consultorios Integrados Rosario
      • Rosario, Santa Fe Province, Argentina, S200DBS
        • Centro de Investigaciones Clinicas - Instituto de la Salud Rosario
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, T4000IHE
        • Clinica Mayo, UMCB
    • Arizona
      • Gilbert, Arizona, Forenede Stater, 85234
        • San Tan Allergy & Asthma
    • California
      • Bakersfield, California, Forenede Stater, 93301
        • Kern Research
      • Fresno, California, Forenede Stater, 93720
        • Central California Clinical Research
      • Los Angeles, California, Forenede Stater, 90027
        • Children's Hospital of Los Angeles
      • Los Angeles, California, Forenede Stater, 90006
        • Sensa Health
      • Orange, California, Forenede Stater, 92868
        • Children's Hospital of Orange County
      • Redwood City, California, Forenede Stater, 94063
        • Allergy and Asthma Consultants
      • Roseville, California, Forenede Stater, 95661
        • Sacramento ENT
      • San Diego, California, Forenede Stater, 92123
        • Rady Children's Hospital San Diego
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60657
        • Chicago ENT
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40205
        • Kentuckiana ENT
    • New York
      • Rochester, New York, Forenede Stater, 14642
        • University of Rochester
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Allergy Asthma & Immunology Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73120
        • Allergy, Asthma & Clinical Research Center
      • Tulsa, Oklahoma, Forenede Stater, 74136
        • Vital Prospects Clinical Research Institute, P.C.
    • South Carolina
      • Orangeburg, South Carolina, Forenede Stater, 29118
        • Carolina ENT
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229
        • STAAMP Research
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84132
        • University of Utah
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23507
        • Eastern Virginia Medical School - Otolaryngology
    • Washington
      • Spokane Valley, Washington, Forenede Stater, 99216
        • Spokane ENT

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

  2. Female subjects, if sexually active, must,

    1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline).

  4. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening).

  5. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over a 7 day period during the single-blind run-in period. (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)

  6. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2015 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study (GINA 2015). Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.

  7. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). [Note: intranasal antibiotics and saline are permissible]

  8. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.

  9. Subjects (with assistance from parent or legal guardian if needed) must demonstrate the ability to complete the daily diary during the run-in period to be eligible for randomization.

  10. Must demonstrate correct use of the demo EDS.

  11. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Has a history of cystic fibrosis
  3. Have used XHANCE (fluticasone propionate) nasal spray within the past 2 months
  4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
  5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
  6. Have known history of nasal septum erosion, ulceration or perforation, or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
  7. Other significant nasal pathology or abnormal anatomy
  8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
  9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  10. Have had any surgery on the nasal septum
  11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
  12. History of any surgical procedure that prevents the ability to accurately diagnose or grade polyps
  13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  14. Have significant oral structural abnormalities (e.g., a cleft palate)
  15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks.
  17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids
  18. Have a hypersensitivity to any excipients in the study drug
  19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
  20. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1
  21. Have nasal or oral candidiasis
  22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)
  23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
  24. History or current diagnosis of any form of glaucoma or ocular hypertension (i.e., >21 mm Hg)
  25. History of intraocular pressure elevation on any form of steroid therapy
  26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
  27. A recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse or dependence
  28. Positive urine drug screen at screening visit for stimulants, opioids, or cocaine
  29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)
  30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: OPN-375 186 μg BID

Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks

Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks

OPN-375, BID

Placebo komparator: Placebo

Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks

OPN-375, BID

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4
Tidsramme: 4 Weeks

Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.

4 Weeks
Mean change from baseline at Week 16 in total polyp grade
Tidsramme: 16 Weeks

Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in bilateral polyp grade over time
Tidsramme: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subjects with a ≥1 point improvement in polyp grade
Tidsramme: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subject with a grade of 0 on at least one side of the nose
Tidsramme: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Tidsramme: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Tidsramme: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Tidsramme: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Tidsramme: 16 Weeks

Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)

16 Weeks
The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase
Tidsramme: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Subjects will assess their global impression of change since starting the study drug using the PGIC scale
Tidsramme: 16 Weeks

Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse

16 Weeks
Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).
Tidsramme: 16 Weeks

Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).

16 Weeks
Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

The assessment criteria are as follows:

  • Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.
  • Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.
  • Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.
  • Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.
Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sikkerhedsvurdering ud fra indsamling af information om samtidig brug af medicin
Tidsramme: 16 uger
16 uger
Assessment of safety from physical examination-measuring weight
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-weight measured in kg or lb

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring height
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-height measured in cm or in

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by recording the severity of AEs
Tidsramme: 16 Weeks

Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

16 Weeks
Assessment of safety by nasal examination
Tidsramme: 16 Weeks

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

16 Weeks
Assessment of safety by ocular examination-visual acuity
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Intraocular Pressure
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Cataract Evaluation
Tidsramme: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety measuring vital signs (blood pressure)
Tidsramme: 16 Weeks

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

16 Weeks
Assessment of safety measuring vital signs (pulse)
Tidsramme: 16 Weeks

measure pulse in beats per minute (bpm)

16 Weeks
Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-∞) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUCex (%)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - Cmax (pg/mL)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - tmax (h)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - t1/2 (h)
Tidsramme: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studiestol: Amy Manley, Paratek Pharma

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. december 2018

Primær færdiggørelse (Faktiske)

31. marts 2026

Studieafslutning (Faktiske)

11. juni 2026

Datoer for studieregistrering

Først indsendt

23. oktober 2018

Først indsendt, der opfyldte QC-kriterier

16. november 2018

Først opslået (Faktiske)

20. november 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • OPN-FLU-NP-3103

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner